Po
Polyphor
Allschwil CHFounded 200150 employees
Private CapbiotechAcquiredInfectious Disease
Platform: Balixafortide CXCR4
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
2
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| POL-5703 | POL-5703 | Approved | 3 | EZH2 | Migraine | ||
| POL-2127 | POL-2127 | Approved | 1 | CD19 | RCC | ||
| Fixabrutinib | POL-6278 | Phase 1 | 1 | MET | FSGSRB | ||
| POL-2929 | POL-2929 | Phase 2/3 | 1 | GPRC5D | EoEEndometrial Ca |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)